Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study

por Joshi, Amit, Kate, Shruti, Noronha, Vanita, Patil, Vijay, Trivedi, Vaishakhi, Goud, Supriya, More, Sucheta, Bhairva, Sandeep, Prabhash, Kumar
Publicado 2018

Audit of screen failure in 15 randomised studies from a low and middle-income country

por Parekh, Deevyashali, Patil, Vijay M, Nawale, Kavita, Noronha, Vanita, Menon, Nandini, More, Sucheta, Goud, Supriya, Jain, Srushti, Mathrudev, Vijayalakshmi, Peelay, Zoya, Dhumal, Sachin, Jogdhankar, Shweta, Prabhash, Kumar
Publicado 2022

An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings

por Kapoor, Akhil, Noronha, Vanita, Joshi, Amit, Patil, Vijay M, Menon, Nandini, Bollam, Rajesh, Talreja, Vikas, Goud, Supriya, More, Sucheta, Solanki, Leena, Shah, Srushti, Chougule, Anuradha, Mahajan, Abhishek, Prabhash, Kumar
Publicado 2021

Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell l...

por Patil, Vijay, Joshi, Amit, Noronha, Vanita, Agarwala, Vivek, Chougule, Anuradha, Kanan, Sadhana, Bhattacharjee, Atanu, Chandrasekharan, Arun, Pande, Nikhil, Simha, Vijai, Goud, Supriya, More, Sucheta, Kumar, Rajiv, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Publicado 2019

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy

por Noronha, Vanita, Patil, Vijay, Joshi, Amit, Chougule, Anuradha, Bhattacharjee, Atanu, Kumar, Rajiv, More, Sucheta, Goud, Supriya, Karpe, Ashay, Ramaswamy, Anant, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Publicado 2017

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?

por Joshi, Amit, Patil, Vijay, Noronha, Vanita, Chougule, Anuradha, Bhattacharjee, Atanu, Kumar, Rajiv, Goud, Supriya, More, Sucheta, Ramaswamy, Anant, Karpe, Ashay, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Publicado 2018

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

por Joshi, Amit, Noronha, Vanita, Patil, Vijay M., Chougule, Anuradha, Bhattacharjee, Atanu, Kumar, Rajiv, Goud, Supriya, More, Sucheta, Ramaswamy, Anant, Karpe, Ashay, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Publicado 2017

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma

por Patil, Vijay Maruti, Noronha, Vanita, Joshi, Amit, Choughule, Anuradha Bharat, Bhattacharjee, Atanu, Kumar, Rajiv, Goud, Supriya, More, Sucheta, Ramaswamy, Anant, Karpe, Ashay, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Publicado 2017

Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer

por Patil, Vijay, Noronha, Vanita, Joshi, Amit, Chougule, Anuradha, Kannan, Sadhana, Bhattacharjee, Atanu, Goud, Supriya, More, Sucheta, Chandrasekharan, Arun, Menon, Nandini, Srinivas, Sujay, Vallathol, Dilip Harindran, Dsouza, Hollis, Majumdar, Swaratika, Das, Sudeep, Zawar, Abhinav, Khaddar, Satvik, Kumar, Amit, Singh, Gunjesh, Kumar, Kanteti Aditya Pavan, Ravind, Rahul, Trivedi, Vaishakhi, Behel, Vichitra, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Publicado 2019